디지털 진단 소프트웨어 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the digital diagnostics software market size is expected to increase from USD 4.56 billion in 2025 to USD 5.23 billion in 2026 and reach USD 9.35 billion by 2031, growing at a CAGR of 12.33% over 2026-2031.

This report is Segmented by Product Type (Diagnostic Imaging, Clinical Decision Support, Others), Deployment Mode (Cloud/SaaS, On-Premises, Hybrid), Diagnostic Modality (Imaging-Based, Signal-Based, IVD and Molecular, and More), Application (Cardiology, Oncology, and More), End User (Hospitals, Labs, and More), and Geography (North America, Europe, APAC, Middle East, South America).

Global Digital Diagnostics Software Market Trends and Insights

Rising Demand for Faster Triage and Early Disease Detection

Emergency and primary care teams are adopting AI-assisted triage tools as imaging demand and physician shortages place more pressure on diagnostic services. A 2026 clinical study found that AI assistance in chest radiograph interpretation reduced junior radiologist report revisions and accelerated senior review, which can shorten the review cycle in high-volume institutions. The result supports demand for tools that help clinicians prioritize urgent cases without replacing clinical oversight. As software moves closer to first-line screening, providers need outputs that can be reviewed and explained during quality assurance and medicolegal review. This need favors systems that fit existing reporting processes and retain clear records of how the software supported a finding. In the digital diagnostics software market, faster triage therefore raises the value of workflow design and accountability alongside diagnostic performance.

Expansion of AI-Enabled Radiology and Pathology Workflows

AI is becoming part of the daily operating workflow in radiology and pathology rather than a separate tool used for selected cases. Yale New Haven Health deployed Rad AI across 16 outpatient imaging centers and 5 hospital campuses in June 2026, covering more than 700,000 annual examinations. The deployment showed that health systems place substantial weight on whether a platform can work across sites and existing systems. PathAI and MedStar Health also announced a multiyear partnership in April 2026 to deploy the AISight Dx digital pathology platform across a laboratory network of more than 40 pathologists. These deployments place emphasis on physician time and operational consistency, which broadens the group of hospital leaders involved in purchasing decisions. The digital diagnostics software market benefits when a platform can be extended across departments without requiring a separate technology project for each clinical use.

Algorithm Explainability and Clinical Liability Concerns

Liability has become a direct procurement consideration for AI-assisted diagnostic tools. California AB-2575 addresses clinical decision support systems and reinforces the importance of clear governance for healthcare AI deployment. The American Medical Association noted in 2025 that guidance on AI explainability remained an active issue for clinical use. Providers need to understand how an output entered the clinical workflow, who reviewed it, and where final responsibility rests. This can favor suppliers that can offer detailed audit records, stronger governance support, and contractual assurance. The digital diagnostics software market may therefore see larger vendors benefit where customers place a premium on risk management.

Other drivers and restraints analyzed in the detailed report include:

1. Multi-Modal Clinical Data Convergence
2. Provider Push Toward Workflow Automation
3. High Integration and Validation Costs Across PACS, EHR, and LIS

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

By Product Type: Image Analysis Expands the Role of Imaging Informatics

Diagnostic Imaging Software held 30.2% of 2025 revenue, making it the largest product category in the digital diagnostics software market. Its position reflects the extensive installed base of radiology departments that rely on PACS-integrated systems for routine image reading, reporting, storage, and communication between care teams. Image Analysis and Computer Vision Software is forecast to grow at a 13.3% CAGR through 2031 as providers introduce tools for lesion detection, segmentation, prioritization, and volumetric measurement. These functions address tasks that can consume substantial specialist time when imaging volumes are high and reporting windows are limited. Clinical Decision Support Software is gaining relevance in primary care, while Laboratory and In Vitro Diagnostics Software advances with laboratory automation and the need to work with existing information systems.

Pathology and Digital Microscopy Software is growing alongside the adoption of digitized whole-slide imaging, which gives laboratories a practical foundation for centralized review and software-supported analysis. Mayo Clinic reported in 2025 that Techcyte Fusion Anatomic Pathology supported its digital pathology transformation, showing that AI-enabled image management can be used across a large laboratory setting without separating the technology from routine workflows. Fujifilm launched an AI-based interstitial lung disease analysis software product in Japan in July 2025 after regulatory certification, linking product development with local clinical and regulatory requirements. The digital diagnostics software industry is seeing value shift toward products that fit established imaging workflows instead of requiring clinicians to work in separate reading environments. This favors suppliers that can combine image analysis, reporting, storage, audit functions, and enterprise workflow tools in a clinically coherent offering.

Cloud-Based and Software-as-a-Service deployment held 55.8% of 2025 revenue, the largest share of the digital diagnostics software market. The approach supports model updates, multisite coordination, and access to shared software services without maintaining separate hardware and version control processes at every location. It also helps providers apply the same workflow rules, user access controls, and software versions across distributed hospital and imaging networks. On-premises systems remain relevant where data residency requirements, local governance, or established infrastructure shape hospital preferences. Hybrid deployment is becoming an option when providers keep sensitive data locally while using cloud resources for selected computing, integration, and workflow tasks.

Cloud deployment also changes the position of legacy PACS vendors, which can offer diagnostic software as part of a broader managed service rather than as a separate technology purchase. Sectra activated its digital pathology module at Guelph General Hospital in February 2026 through the hospital's existing Sectra One Cloud platform. The case shows how a cloud platform used for one imaging area can support an adjacent diagnostic module, drawing on familiar infrastructure and established user relationships. This can reduce the need for a separate procurement project, simplify implementation, and make it easier for clinical teams to adopt additional digital functions. In the digital diagnostics software market, this creates a distribution advantage for suppliers whose platforms can add new modules while preserving interoperability with the customer's wider information environment.

Complete Report Scope:

• Market Size and Growth Forecast by Value
• Product and Offering
  • Predictive Diagnostic Software Platforms
  • Clinical Decision Support Modules
  • Diagnostic Risk-Stratification Engines
  • Predictive Monitoring and Early-Warning Applications
  • Implementation, Integration, and Managed Services
  • Maintenance, Validation, and Model-Governance Services
• Analytics Function
  • Predictive Analytics
  • Diagnostic Analytics
  • Prescriptive Analytics
  • Cognitive Analytics
  • Risk Scoring and Stratification
  • Anomaly Detection and Early Warning
• Deployment
  • On-Premises
  • Cloud-Based
  • Hybrid
  • Edge and Embedded Deployment
• Application
  • Clinical Diagnostics
  • Patient Deterioration and Sepsis Prediction
  • Readmission, Length-of-Stay, and Mortality Prediction
  • Preventive and Population Risk Management
  • Treatment Response and Therapy Optimization
  • Remote Patient Monitoring and Home-Based Care
  • Clinical Trial and Real-World Evidence Analytics
  • Diagnostic Utilization and Stewardship
• Segmentation by End User
  • Hospitals and Health Systems
  • Physician Groups and Clinics
  • Diagnostic Laboratories and Pathology Networks
  • Payers and Accountable Care Organizations
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes and Academic Medical Centers
  • Public Health Agencies
• Segmentation by Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.1% of the digital diagnostics software market in 2025, reflecting mature health record infrastructure, active payer experimentation, and a high concentration of diagnostic software providers. Health systems in the region are moving from separate AI tools toward platforms that manage workflow across imaging sites, outpatient centers, and hospital departments. Yale New Haven Health's 2026 deployment of Rad AI across 5 hospital campuses and 16 outpatient centers shows the scale of this operating model. Canada is also extending adoption beyond major academic centers, as shown by the February 2026 activation of Sectra Digital Pathology at Guelph General Hospital.

Europe is adopting diagnostic AI within a compliance-focused environment shaped by the European Union's AI Act and medical device requirements. These requirements can raise the quality threshold for tools that reach the market while adding time and cost for developers. Germany's Asklepios hospital group deployed Aidoc's aiOS across more than 25 clinic sites in 2025 through hospital digitization funding. The United Kingdom, France, and Nordic countries are progressing with digital pathology and imaging AI procurement, while Spain and Italy remain earlier in the adoption cycle.

Asia Pacific is forecast to grow at a 12.6% CAGR through 2031, the fastest regional rate in the digital diagnostics software market. China's county-level remote diagnostic imaging services exceeded 68 million encounters in 2025, demonstrating the scale of demand for remote diagnostic capacity. China's clinical need and large health service network make remote review and AI-assisted triage especially relevant. Japan has an expanding pipeline of regulated software, including AI Medical Service's gastroAI model-G2 for early gastric cancer and adenoma detection in 2025. The Middle East and South America are earlier-stage markets where adoption is concentrated in tertiary referral centers and government-supported telemedicine infrastructure. Gulf Cooperation Council countries show the most active procurement in the Middle East, while the broader regional opportunity depends on clinical infrastructure and specialist availability.

1. CitiusTech
2. Cotiviti, Inc.
3. Datavant
4. Epic Systems
5. GE HealthCare Technologies Inc.
6. Health Catalyst, Inc.
7. IBM
8. Inovalon, Inc.
9. IQVIA
10. Komodo Health, Inc.
11. Mckesson
12. MedeAnalytics
13. Merative
14. Microsoft
15. Optum
16. Oracle
17. Koninklijke Philips
18. SAS Institute
19. Siemens Healthineers
20. Tempus AI, Inc.
21. Veradigm

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expanding Multimodal Clinical Data Availability
  • 4.2.2 Shift Toward Proactive and Value-Based Care
  • 4.2.3 Integration of Predictive Models Into EHR Workflows
  • 4.2.4 Rising Demand for Earlier Detection of High-Cost Conditions
  • 4.2.5 Cloud and AI Infrastructure Lowering Deployment Barriers
  • 4.2.6 Underdiagnosed Disease Pathways Creating White Space for Risk Stratification
• 4.3 Market Restraints
  • 4.3.1 Data Interoperability and Longitudinal Record Fragmentation
  • 4.3.2 Clinical Liability and Trust in False Positives or False Negatives
  • 4.3.3 Shortage of Clinical AI Validation and Implementation Skills
  • 4.3.4 Model Drift, Bias, and Post-Deployment Monitoring Burden
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis

5 MARKET SIZE AND GROWTH FORECASTS

• 5.1 Market Size and Growth Forecast by Value
• 5.2 Product and Offering
  • 5.2.1 Predictive Diagnostic Software Platforms
  • 5.2.2 Clinical Decision Support Modules
  • 5.2.3 Diagnostic Risk-Stratification Engines
  • 5.2.4 Predictive Monitoring and Early-Warning Applications
  • 5.2.5 Implementation, Integration, and Managed Services
  • 5.2.6 Maintenance, Validation, and Model-Governance Services
• 5.3 Analytics Function
  • 5.3.1 Predictive Analytics
  • 5.3.2 Diagnostic Analytics
  • 5.3.3 Prescriptive Analytics
  • 5.3.4 Cognitive Analytics
  • 5.3.5 Risk Scoring and Stratification
  • 5.3.6 Anomaly Detection and Early Warning
• 5.4 Deployment
  • 5.4.1 On-Premises
  • 5.4.2 Cloud-Based
  • 5.4.3 Hybrid
  • 5.4.4 Edge and Embedded Deployment
• 5.5 Application
  • 5.5.1 Clinical Diagnostics
  • 5.5.2 Patient Deterioration and Sepsis Prediction
  • 5.5.3 Readmission, Length-of-Stay, and Mortality Prediction
  • 5.5.4 Preventive and Population Risk Management
  • 5.5.5 Treatment Response and Therapy Optimization
  • 5.5.6 Remote Patient Monitoring and Home-Based Care
  • 5.5.7 Clinical Trial and Real-World Evidence Analytics
  • 5.5.8 Diagnostic Utilization and Stewardship
• 5.6 Segmentation by End User
  • 5.6.1 Hospitals and Health Systems
  • 5.6.2 Physician Groups and Clinics
  • 5.6.3 Diagnostic Laboratories and Pathology Networks
  • 5.6.4 Payers and Accountable Care Organizations
  • 5.6.5 Pharmaceutical and Biotechnology Companies
  • 5.6.6 Research Institutes and Academic Medical Centers
  • 5.6.7 Public Health Agencies
• 5.7 Segmentation by Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 South Korea
    • 5.7.3.5 Australia
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 CitiusTech Inc.
  • 6.3.2 Cotiviti, Inc.
  • 6.3.3 Datavant
  • 6.3.4 Epic Systems Corporation
  • 6.3.5 GE HealthCare Technologies Inc.
  • 6.3.6 Health Catalyst, Inc.
  • 6.3.7 International Business Machines Corporation (IBM)
  • 6.3.8 Inovalon, Inc.
  • 6.3.9 IQVIA Holdings Inc.
  • 6.3.10 Komodo Health, Inc.
  • 6.3.11 McKesson Corporation
  • 6.3.12 MedeAnalytics, Inc.
  • 6.3.13 Merative
  • 6.3.14 Microsoft Corporation
  • 6.3.15 Optum, Inc.
  • 6.3.16 Oracle Corporation
  • 6.3.17 Koninklijke Philips N.V.
  • 6.3.18 SAS Institute Inc.
  • 6.3.19 Siemens Healthineers AG
  • 6.3.20 Tempus AI, Inc.
  • 6.3.21 Veradigm LLC

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment